Epirubicin Market

Epirubicin Market Outlook (2022 to 2032)

The epirubicin market is anticipated to grow at a CAGR of 3.6% during the forecast period and is anticipated to reach US$ 198.56 Million in 2022. It is anticipated that sales of epirubicin would exceed US$ 282.81 Million by 2032.

Epirubicin hydrochloride (HCl), a member of the anthracycline medication family, is typically used to treat breast cancer following surgical resection. A class of antibiotics known as anthracyclines was discovered in the gram-positive bacterium Streptomyces.

They are frequently employed as chemotherapy drugs, and by concentrating on DNA replication, they have anti-cancer effects. Since epirubicin HCl has been demonstrated to have less adverse effects than anthracycline doxorubicin, it is frequently chosen.

The rising rate of cancer and widespread consciousness of cancer are the dominant elements driving the market expansion. Furthermore, the market for epirubicin is probably going to have economic prospects due to the expanding pharmaceutical sector worldwide. Sales of epirubicin are also being driven by an increase in demand for palliative care medications as a result of an increasing geriatric population.

Preference for epirubicin is increasing among end-users as it is used to treat lung, ovarian, and breast malignancies. By destroying any leftover tumor cells after surgery or radiation therapy has mostly eliminated them, it lowers the probability of recurrence.

Epirubicin is provided by manufacturers in a number of pharmaceutical formulations, including injections and intravenous infusions. The usage of some of the key applications is intended for hospital pharmacies, retail pharmacies, and online pharmacies.

Report Attributes	Details
Current Valuation of Epirubicin Market (2022)	US$ 198.56 Million
Projected Epirubicin Market Value (2032)	US$ 282.81 Million
Global Epirubicin Market Growth Rate	3.6%
Hospital Pharmacy Growth Rate	4%
US Epirubicin Market Growth Rate	5.2%
German Epirubicin Market Growth Rate	4.3%
Breast Cancer Growth Rate	8.3%
Asia Pacific Epirubicin Market Growth Rate	4%
Key Companies Profiled	Pfizer, Inc.; Teva Pharmaceutical Industries Ltd; Salius Pharma Pvt Ltd; Areva Pharmaceuticals; Mylan N. V.; Hikma Pharmaceuticals PLC; Fresenius Kabi AG; Hologic Inc; Miracalus Pharma Pvt.

Why does it Epirubicin Market is Witnessing a Substantial Shift around the world?

Rising Cases of Cancer

Owing to the increasing number of cancer cases and patient awareness, the inclination towards epirubicin is escalating globally. Since epirubicin is a medication used to treat cancer, there is a growing preference for it. An estimated 38 million individuals each year pass away from non-communicable illnesses, like cancer, according to the American Cancer Society (ACS).

The sales of epirubicin are also anticipated to increase due to the rising incidence of breast cancer. The occurrence of cancer is increasing in women population across the world. The International Agency for Research on Cancer (WHO) estimates that in 2020, there were 2,261,419 cases reported of breast cancer, accounting for almost 11.7% of the overall cancer cases worldwide. So it is anticipated that the high prevalence and mortality rate of breast cancer would have a substantial influence, propelling the market growth.

The sales of epirubicin are also expected to benefit from the development of novel non-drug and improved chemotherapeutic drugs, among other things. Most physicians use epirubicin as a chemotherapeutic drug after early-stage cancer surgery to stop the spread of harmful cells, which will increase the demand for it.

Government Support and Rise in Healthcare Infrastructure

The factors that will propel the global anthracyclines market to grow include a boost in healthcare expenses, rising economies, and increased government measures to raise awareness of the condition. Governments from several nations are also putting plans into action to assist developments in clinical cancer technology, such as intravenous free treatment and digital microfluidics for on-chip biochemical analysis. Programs to raise awareness of cancer treatment are also being expanded. The demand for epirubicin has consequently increased significantly.

Furthermore, to create scientifically advanced epirubicin formulations, researchers are investing a lot of money in clinical trials. In addition, a good outlook for the market in the next years is anticipated due to the rising number of mergers and acquisitions as well as collaborations for clinical studies using enhanced versions of epirubicin. Hence, the overall prospects for this market are also driven by the growth and innovation in healthcare infrastructure as well as medicine affordability throughout the projection period.

What Factors are Preventing the Epirubicin Market from Getting bigger?

Epirubicin Possess some Side-effects

The variables that would impede market expansion and provide new obstacles for the global market during the aforementioned forecast period are adverse drug reactions including bleeding, skin ulcers, tissue necrosis, and others, as well as difficulties related to drug administration.

What Elements are likely to provide the Epirubicin Market Potential Opportunities?

The Expanding Pharmaceutical Sector Worldwide

The market for epirubicin is probably going to have growth prospects due to the expanding pharmaceutical sector globally. To bring the pharmaceutical sector together in a push for improved business practices, more streamlined companies, eliminating waste, and recognizing possibilities, the FDA launched the industry's drive for continuous improvement in 2004. Therefore, factors like rising R&D spending and an increase in patent applications are what drive the industry.

Furthermore, pharmaceutical companies like Astra Zeneca, Eli Lilly, and GSK have made substantial contributions to the industry's expansion and have spearheaded research and development during its zenith. In the upcoming years, market growth is anticipated to be influenced by the expansion of these firms and business sectors.

Segmentation Insights

Why does the Breast Cancer Segment Account for a Lion's Share of the Market in Terms of Revenue?

Based on application, the epirubicin market is classified into breast cancer, liver cancer, bladder cancer, and others. The breast cancer segment dominated the market among others. This segment is anticipated to grow at a CAGR of 8.3% during the forecast period.

The global breast cancer segment is expected to rise throughout the projection period as a result of rising alcohol consumption among women worldwide, rising obesity rates, and rising radiation exposure risks. Epirubicin was initially introduced primarily to treat patients with breast cancer.

Why does the Hospital Pharmacies Segment Hold such a Broad Niche?

Depending on the distribution channel, the epirubicin market is categorized into hospitals pharmacies, retail pharmacies, and online pharmacies The segment of hospital pharmacies is anticipated to have the greatest market share worldwide and is expected to exhibit a CAGR of 4% during the forecast period due to the growing need for anti-cancer medications from hospitals as a consequence of the increase in cancer incidence.

The potential to service a wider patient pool and the increasing number of patients entering hospital settings are two variables that influence segment demand. Hospital pharmacies provide greater accessibility to advanced treatment alternatives for some chronic illnesses, like cancer. Family members prefer to buy these medications from hospital pharmacies itself. Additionally, having a wide range of services and qualified medical professionals under one roof is beneficial for the expansion of the hospital segment.

Regional Perspectives

Why is North America becoming more Significant as a Nexus for the Epirubicin Market?

Owing to the existence of several major key companies, North America owns and controls the epirubicin market.

What Significant Potential Does the US Provide in the Epirubicin Market?

The largest market is the US, which is expanding at an average CAGR of 5.2%. The US spends more resources than any other nation on cancer treatment and research. The US population supports 44% of all cancer research globally.

The US pharmaceutical market, on the other hand, is the biggest and most developed in North America. Over 45% of the global pharmaceutical industry was dominated by only the US. The US has been at the forefront of biomedical research, and the bulk of the top global drug production corporations are based here.

The preference for epirubicin in the US is impacted by the increased occurrence of cancer cases and the resulting rise in the use of epirubicin in single-agent and multi-agent chemotherapy. The key elements propelling the US epirubicin market are the rising number of mergers and acquisitions as well as collaborations for clinical studies using cutting-edge epirubicin formulations.

What Reforms Are Expected in the European Epirubicin Market?

Europe has a high demand for epirubicin, which is anticipated to increase rapidly all through the forecast period. The growing incidence of infectious diseases and cancer cases, as well as increased investment in R&D, are all contributing to the region's market growth expectations.

The European epirubicin market will be driven by factors such as the rising incidence of chronic illnesses like cancer, rising research and development efforts by several significant companies, rising patient care costs, and rising demand for enteral nutrition over the forecast period.

Why Did the German Epirubicin Market Acquire the Highest Profit Share in Europe?

Germany is expected to expand within Europe at a CAGR of around 4.3%. The need for breast cancer therapies is expected to increase due to the nation's increasing illness burden.

The International Trade Administration (ITA) estimates that the German pharmaceutical industry was worth USD 62.5 billion in 2019. Due to rising investments in R&D and rising patent applications, the nation is projected to continue to rank among the most desirable locations for the global pharmaceutical sector in terms of manufacturing and supply.

Why is the Asia Pacific Market for Epirubicin Emerging as a Potential Region?

Asia Pacific is another important market because of the region's increasing cancer mortality, increased awareness of different cancer treatments, and expanding partnerships between the public and private sectors to provide novel cancer treatments there. The Asia Pacific epirubicin market is estimated to increase from US$ 29.67 Million in 2022 to US$ 43.80 Million by 2032, expanding at a CAGR of 4.0%.

China and Japan are two emerging nations that are making significant investments in infrastructure and industrial growth. Market expansion will be pushed by firms operating in these two countries focusing more on the research and development of innovative medications to treat severe and chronic illnesses. These businesses will gain from the government's increasing support for the expansion of domestic medication development and production.

What Does the Growth Prospect for the Chinese Epirubicin Market Appear Like?

Growing at a CAGR of 4.8%, China holds the largest market share in the Asia Pacific. The expansion of this market is mainly credited to the expanding pharmaceutical sector, rising advancements by market participants, and favorable regulatory regulations by the government. Furthermore, success in reducing China's cancer burden depends on the industry's ability to innovate more quickly. The Chinese epirubicin market is expanding rapidly, exceeding the pace of the increase of new cancer cases there.

Additionally, China's overpopulation and the increased incidence of cancer are both significantly driving up demand for cancer medications. Hence, the need for cancer treatment is projected to rise due to China's rising cancer prevalence. According to the WHO data, China witnessed 3,002,899 cancer-related fatalities and 4,568,754 new cases of cancer in 2020. As a result, it is anticipated that the country's demand for cancer drugs and vaccines would increase due to a large number of cancer patients and product and treatment improvements by market participants.

Why does Japan have so Strong Development Potential?

According to trends seen globally, the epirubicin business in Japan is expected to increase at an optimistic CAGR of 3.8% over the projected period. The market introduction of various cutting-edge drugs by local and international businesses operating in Japan has boosted total sales levels in recent years.

After breast and lung cancer, stomach cancer is the third most prevalent kind of cancer illness. Significant prostate and lung cancer cases are reported annually in this state owing to the rising elderly population. The main drivers of the Japanese epirubicin market's above-average growth include R&D investment for new medication inventions and the accessibility of targeted pharmacological therapy.

Comparative Analysis of Adjacent Markets

Epirubicin Market :

Differentiating Aspects	Epirubicin Market
CAGR	3.6%
Market Valuation in 2022	US$ 198.56 Million
Projected Market Value in 2032	US$ 282.81 Million
Growth Factor	This market is growing substantially across the world as a result of the rise in cancer cases and patient awareness.
Opportunity	Pharmaceutical businesses have been at the forefront of research and development when the sector was at its peak and are now significantly contributing to its growth.
Key Trend	The synthesis of classic nondrug and improved chemotherapy drugs.

Cancer Therapy Market :

Differentiating Aspects	Cancer Therapy Market
CAGR	9%
Market Valuation in 2022	US$ 189.86 Bn
Projected Market Value in 2032	US$ 449.46 Bn
Growth Factor	To properly treat patients, there will likely be greater demand for advanced cancer treatments as the number of cancer cases rises.
Opportunity	Globally, the incidence of cancer is rising along with patient assistance programs (PAPs) and government initiatives to raise cancer awareness.
Key Trend	Some of the key trends are major companies investing in R&D and the rising requirement for personalized medicine.

Oncology Drugs Market :

Differentiating Aspects	Oncology Drugs Market
CAGR	7.5%
Market Valuation in 2022	US$ 156.01 Bn
Projected Market Value in 2032	US$ 321.55 Bn
Growth Factor	An increase in cancer awareness and early cancer detection are helping the market for oncology medications to expand.
Opportunity	The enormous prospective of developing countries and the vast number of potential medications in development are anticipated to provide profitable potential.
Key Trend	The global ageing population is increasing, and the use of advanced medicines (such as specialized drug therapy) is expanding simultaneously.

Competitive Landscape

The competitive landscape of epirubicin market is a fragment of pharmaceutical business that makes it vibrant and extremely profitable. Furthermore, businesses collaborate and combine with other businesses, which deepens their foundations and increases the number of production and distribution facilities they have.

The focus of the market participants is on developing innovative approaches to improve patient care. Owing to the clever movements made by market players and advancements in the drug epirubicin, a wider range of medications are now more easily available.

Epirubicin producers are moving more quickly to get licenses for their drugs so that mass production may start. To strengthen their positions in the market, the players are employing a variety of strategies, including partnerships, product launches, mergers and acquisitions, and innovations.

Recent Developments :

Date	Company Name	Strategy	Details
August 2021	Pfizer Inc.	Agreement	Pfizer Inc. and Trillium Therapeutics Inc. signed a legally binding agreement under which Pfizer would purchase Trillium, an immuno-oncology business that is currently researching novel cancer medicines. Following the terms of the deal, Pfizer will purchase all outstanding shares of Trillium that it does not already own for $ 2.26 billion, or $ 18.50 per share, in cash, which represents the implied equity value.
January 2021	Hologic Inc.	Acquisition	SOMATEX Medical Technologies GmbH and Biotheranostics were obtained by Hologic Inc. By acquiring these businesses, the company was able to bolster its position and increase the number of breast health products it offers.
December 2018	Teva Pharmaceutical Industries Ltd	Launch	Teva Pharmaceutical Industries Ltd. and Celltrion, Inc. revealed that the U.S. Food and Drug Administration (FDA) has authorised the introduction of HERZUMA®, a HER2/neu receptor antagonist biosimilar to HERCEPTIN® for the treatment of HER2-overexpressing breast cancer for certain indications.
April 2018	Hikma Pharmaceuticals PLC	Launch	Hikma Pharmaceuticals PLC proclaimed that it’s solely possessed US subsidiary West-Ward Pharmaceuticals Corp. has introduced Epirubicin Hydrochloride Injection, USP, 50mg/25mL and 200mg/100mL vials, the generic equivalent to Ellence®.

Key Segments

• By Dosage :

  • 10mg/Vial
  • 50mg/Vial
  • 100mg/Vial
  • 200mg/Vial

• By Application :

  • Breast Cancer
  • Liver Cancer
  • Bladder Cancer
  • Others

• By Distribution Channel :

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

• By Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA